Tests HPV vaccine Gardasil 9 in adults after stem cell transplant
Tests timing of the HPV vaccine Gardasil 9 in adults after a stem cell transplant.
Plain-language title generated from the registry record
Registry title: Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Key facts
- Where
- Gothenburg, Linköping, Lund, Stockholm, and Uppsala, SwedenSee the 5 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT06793410, who can take part
Where in Sweden
- Sahlgrenska University HospitalGothenburg, SwedenTaking people
- Linkoping University HospitalLinköping, SwedenTaking people
- Skåne's University HospitalLund, SwedenNot yet recruiting
- Karolinska University HospitalStockholm, SwedenNot yet recruiting
- Uppsala University HospitalUppsala, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vastra Gotaland Region
- Trial code
- NCT06793410
- Record updated
- 5 June 2025
- Original description
Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases. For several reasons, these patients have a long-term immune deficiency due to the transplant itself (lack of immune reconstitution) and due to possible complications, primarily GvHD and its treatment. The risk of secondary malignancy in the long-term following an allogeneic bone marrow transplant is greatly increased, and secondary cancer cases account for a significant proportion of late deaths in both women and men after transplantation. Some of these secondary cancers are associated with HPV. The risk of cervical cancer has been reported to be 13 times increased compared to a healthy population.Read full original descriptionShow less
Vaccination Against Human Papillomavirus (HPV) in Women and Men After Stem Cell Transplantation
Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases. For several reasons, these patients have a long-term immune deficiency due to the transplant itself (lack of immune reconstitution) and due to possible complications, primarily GvHD and its treatment. The risk of secondary malignancy in the long-term following an allogeneic bone marrow transplant is greatly increased, and secondary cancer cases account for a significant proportion of late deaths in both women and men after transplantation. Some of these secondary cancers are associated with HPV. The risk of cervical cancer has been reported to be 13 times increased compared to a healthy population.
Therefore in this trial, the aim is to study immune response (antigen-specific antibody response) after vaccination with 9-valent HPV vaccine (Gardasil 9®) in adult women and men (up to and including 45 years of age) who have undergone allogeneic stem cell transplantation. In this trial, the sponsor will compare "early" (start 9 months after tx) with "late" (start 15 months after tx) vaccination.
Inclusion: Recipient of AlloSCT from related or unrelated donor; Adults (men and women) ≥18 years up to and including 45 years of age for vaccination; Patients can be included regardless of prior HPV vaccination prior to transplantation.
Exclusion: Extensive chronic GvHD requiring treatment with prednisone doses above 0.7 mg/kg/day plus at least two other systemic treatments against GvHD (for example ruxolitinib or photopheresis); Treatment with rituximab 6 months before start of vaccination. Doses given later (unusual) do not require exclusion; Treatment within 3 months before start of vaccination with iv or sc immunoglobulin; Pregnancy, pregnancy desire or active pregnancy planning during time vaccine is given and up to three months after last vaccine dose; Treatment with blood thinning medication contraindicating intramuscular injection; Allergy against Gardasil 9; Severe thrombocytopenia (under 50 x 10\^9) not allowing intramuscular injection; Severe acute GvHD grade III-IV; Prednisone doses above 1mg/kg/day at study start.